Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Italy
  4. Borsa Italiana
  5. Recordati
  6. News
  7. Summary
    REC   IT0003828271

RECORDATI

(REC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

RECORDATI: RESIGNATION OF A NON-EXECUTIVE DIRECTOR

10/11/2021 | 01:22pm EST

NEWS RELEASE

RECORDATI: RESIGNATION OF A NON-EXECUTIVE DIRECTOR

Milan, 11th October 2021 - The Company communicates the receipt today of Mr. Francesco Balestrieri's resignation as member of the Board of Directors of the Company, effective as of 15th October, due to a new professional appointment and the consequent incompatibility of the latter with his office as director of the Company.

Mr. Balestrieri is a non-executive Director and, as of today, on the basis of the information available to Recordati S.p.A., does not hold any Company's shares.

The Chairman and the Chief Executive Officer, on behalf of the entire Board of Directors, thank Mr. Balestrieri for his contribution to the Board's work during his term of office and wish him all the best for his new professional appointment.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469.0 million and net income was € 355.0 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Media Relations

Federica De Medici

Brunswick - Barbara Scalchi / Andrea Mormandi

(39) 02 48787146

(39) 02 9288 6200

e-mail: investorelations@recordati.it

e-mail: recordati@brunswickgroup.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1

Share Capital € 26.140.644,50 fully paid-up

20148 Milano, Italy

Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150

Ph. (39) 02 487871

Tax Code/VAT No. 00748210150

Fax (39) 02 40073747

Milano R.E.A. No. 401832

www.recordati.com

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.àr.l

Disclaimer

Recordati S.p.A. published this content on 11 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 October 2021 17:21:04 UTC.


© Publicnow 2021
All news about RECORDATI
01/12ITA Airways seeks an ally to put 'money on the table'
RE
2021Eton Pharmaceuticals, ANI Pharmaceuticals Launch Carglumic Acid Tablets for Hyperammone..
MT
2021RECORDATI : Kim stratton co-opted to the board of directors as a non-executive and non-ind..
PU
2021RECORDATI : Presentazione EUSA Pharma Acquisition
PU
2021RECORDATI : EUSA Pharma Acquisition
PU
2021Recordati To Acquire EUSA Pharma In $847 Million Deal
MT
2021Recordati to buy EUSA Pharma for $847 million to boost rare disease offering
RE
2021RECORDATI : TO ACQUIRE EUSA PHARMA (UK) Ltd, A GLOBAL SPECIALTY PHARMACEUTICAL COMPANY FOC..
PU
2021Recordati Industria Chimica e Farmaceutica S.p.A. agreed to acquire Eusa Pharma (Uk) Li..
CI
2021Recordati's CEO Takes Over Chair Role; New CEO Appointed
MT
More news
Analyst Recommendations on RECORDATI
More recommendations
Financials
Sales 2021 1 579 M 1 792 M 1 792 M
Net income 2021 407 M 462 M 462 M
Net Debt 2021 858 M 973 M 973 M
P/E ratio 2021 26,6x
Yield 2021 2,18%
Capitalization 10 564 M 11 989 M 11 987 M
EV / Sales 2021 7,23x
EV / Sales 2022 6,72x
Nbr of Employees 4 446
Free-Float -
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 51,20 €
Average target price 50,54 €
Spread / Average Target -1,30%
EPS Revisions
Managers and Directors
Robert Koremans Chief Executive Officer
Luigi Felice la Corte Group Chief Financial Officer
Andrea Recordati Chairman
Raffaele Sabia Senior VP-Pharmaceutical Research & Development
Giovanni Minora Head-Group Audit & Compliance
Sector and Competitors
1st jan.Capi. (M$)
RECORDATI-7.58%12 209
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
ELI LILLY AND COMPANY-10.55%223 992